CTIS2022-501152-28-00招募中1 期
A randomized, open-label, phase II trial comparing neoadjuvant endocrine therapy in combination with trastuzumab, pertuzumab +/- the PI3K inhibitor inavolisib in patients with HER2-positive, HR-positive, PIK3CA mutant early breast cancer - GeparPiPPa - GBG 105
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 220
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Written informed consent for all study procedures according to local regulatory requirements prior to beginning specific protocol procedures., Negative pregnancy test, For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods, Complete staging work-up within prior to randomization, Patient must be willing and able to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures., Untreated, unilateral primary carcinoma of the breast, confirmed histologically by core biopsy. Fine-needle aspiration alone is not sufficient. Incisional biopsy is not allowed., Tumor lesion in the breast with a palpable size of = 2 cm or a sonographical size of = 1 cm in maximum diameter. The lesion has to be measurable in two dimensions, preferably by sonography., Patients must be in the following stages of disease: cT1c – cT3. In patients with multifocal or multicentric breast cancer the largest lesion (target lesion) should be measured., HR+/HER2+ disease with centrally confirmed ER-status, PR-status, HER2-status, PIK3CA mutation (tumor), Ki-67 value and TILs on core biopsy (target lesion). ER/PgR positive and HER2-positive is defined according to current ASCO/CAP guidelines. PIK3CA mutational status will be determined by NGS. Formalin-fixed, paraffin-embedded (FFPE) breast tissue from core biopsy has therefore to be sent to the GBG central pathology laboratory prior to randomization., Age >= 18 years, female and male., ECOG Performance status 0-1., Normal cardiac function must be confirmed by ECG and cardiac ultrasound (LVEF or shortening fraction) within 3 months prior to randomization. Results for LVEF must be above 55%., adequate laboratory requirements: Hematology, Hepatic function, Glucose Metabolism
排除标准
- •Patients with HER2-negative breast cancer and/or HER2-positive, HR-negative breast cancer, Patients with an established diagnosis of diabetes mellitus type I or uncontrolled type II based on FPG and HbA1c., Patients who are immunocompromised as the result of HIV or receiving immunosuppressive therapies., Clinically significant and active liver disease, for example, sclerosing cholangitis, active viral hepatitis B or C infection, or autoimmune hepatic disorders., Patients with inflammatory bowel disease, such as Crohn’s disease or ulcerative colitis, and active bowel inflammation (e.g., diverticulitis)., Patients with any concurrent ocular or intraocular condition, such as cataract or diabetic retinopathy, that would require medical or surgical intervention during the study period to prevent or treat vision loss. In addition, patients with active uveitis or vitritis, history of uveitis, or active infectious process in the eye., Patients with currently documented pneumonitis/interstitial lung disease., Known or suspected congestive heart failure (>NYHA I) and / or coronary heart disease, angina pectoris requiring antianginal medication, previous history of myocardial infarction, evidence of transmural infarction on ECG, uncontrolled or poorly controlled arterial hypertension (i.e. BP >160 / 90 mm Hg under treatment with three antihypertensive drugs), rhythm abnormalities requiring permanent treatment, clinically significant valvular heart disease., Damaged skin at planned site of subcutaneous (SC) injections (thigh)., Patients who may have had a recent episode of thromboembolism and are still trying to optimize the anticoagulation dose and/or have not normalized their INR., Concurrent treatment with: • Chronic corticosteroids unless initiated > 6 months prior to study entry and at low dose (10 mg or less methylprednisolone or equivalent). • Sex hormones. Prior treatment must be stopped before study entry. (GnRH a is allowed) • Other experimental drugs or any other anti-cancer therapy., Need of immediate neoadjuvant chemotherapy, e.g. inflammatory breast cancer, Participation in another clinical trial with any investigational, not marketed drug within 30 days prior to study entry., Female patients: pregnancy or lactation at the time of randomization., History of significant neurological or psychiatric disorders including psychotic disorders, dementia or seizures that would prohibit the understanding and giving of informed consent., Any condition that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of patient safety or study results., Patients with definitive clinical or radiologic evidence of Stage IV cancer. 4. Excisional biopsy or lumpectomy and /or axillary lymph node dissection, Excisional biopsy or lumpectomy and /or axillary lymph node dissection and/or sentinel lymph node biopsy performed prior to study entry (biopsy of clinical involved LN is warranted)., Prior chemotherapy or endocrine therapy or radiation therapy prior to study entry., Patients with a history of breast cancer are ineligible with the following exceptions: Patient has been disease-free for more than 5 years and is at low risk for recurrence (at the investigator’s discretion)., Patients with a history of any treated malignancy are ineligible in case of high risk of recurrence (at the investigator’s discretion) and/or ongoing oncological treatment. This also applies to patients who are at high risk that oncolo
研究者
相似试验
进行中（未招募）
1 期
eoadjuvant endocrine therapy in combination with trastuzumab, pertuzumab with or without inavolisibEUCTR2021-002323-38-DEGerman Breast Group170
进行中（未招募）
1 期
A phase II, randomized, open-label study comparing salvage radiotherapy in combination with 6 months of androgen-deprivation therapy (ADT) with LHRH agonist or antagonist versus anti-androgen therapy (AAT) with apalutamide in patients with biochemical progression after radical prostatectomyMedDRA version: 20.0Level: LLTClassification code: 10007113Term: Cancer of prostate Class: 10029104Prostate cancerCTIS2024-512023-37-00GasthuisZusters Antwerpen202
招募中
2 期
A phase II, randomized, open-label study comparing salvage radiotherapy in combination with 6 months of androgen-deprivation therapy (ADT) with LHRH agonist or antagonist versus anti-androgen therapy (AAT) with apalutamide in patients with biochemical progression after radical prostatectomyProstate cancer2024-512023-37-00Ziekenhuis Aan De Stroom202
招募中
1 期
Randomized open-label Phase 2 trial evaluating the impact of enhanced versus standard dermatologic management on selected dermatologic adverse events among patients with first-line locally advanced or metastatic EGFR-mutated NSCLC treated with amivantamab + lazertinibEGFR-mutated Advanced or Metastatic Non-small Cell Lung CancerCTIS2023-505863-35-00Janssen - Cilag International180
进行中（未招募）
1 期
A phase 2 study comparing S 95005 plus bevacizumab to capecitabine plus bevacizumab in patients with previously untreated colorectal cancer who are non-eligible for intensive therapyMetastatic colorectal cancerMedDRA version: 18.1Level: PTClassification code 10052358Term: Colorectal cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-004544-18-ESaboratorios Servier S.L.154